Clinical trials
Completed Phase 3 trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
2,394 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 8 |
| 2001 | 15 |
| 2002 | 19 |
| 2003 | 53 |
| 2004 | 63 |
| 2005 | 64 |
| 2006 | 100 |
| 2007 | 115 |
| 2008 | 136 |
| 2009 | 137 |
| 2010 | 124 |
| 2011 | 171 |
| 2012 | 154 |
| 2013 | 163 |
| 2014 | 153 |
| 2015 | 131 |
| 2016 | 152 |
| 2017 | 145 |
| 2018 | 130 |
| 2019 | 131 |
| 2020 | 111 |
| 2021 | 69 |
| 2022 | 23 |
| 2023 | 10 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 2,394 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 152 |
| Hoffmann-La Roche | 140 |
| GlaxoSmithKline | 121 |
| AstraZeneca | 117 |
| Sanofi | 115 |
| Boehringer Ingelheim | 88 |
| Pfizer | 87 |
| Bristol-Myers Squibb | 84 |
| Novo Nordisk A/S | 82 |
| Eli Lilly and Company | 78 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 173 |
| Diabetes Mellitus | 87 |
| Breast Neoplasms | 82 |
| Asthma | 74 |
| Arthritis, Rheumatoid | 71 |
| Carcinoma, Non-Small-Cell Lung | 71 |
| Pulmonary Disease, Chronic Obstructive | 67 |
| Schizophrenia | 61 |
| Neoplasms | 52 |
| Epilepsy | 40 |
Trials
Showing 1 to 25 of 2,394. Each trial links to its page on Pharma Observatory.
2,294 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.